Dr. Hua Wu

Senior Scientist / VP Vaccine & Antibody Development

As Vice President of Vaccine and Antibody Development, Dr. Wu directs the development of vaccines and immunization programs to produce highly potent fully human therapeutic antibodies from transchromosomal (Tc) bovine. She is also in charge of the development of bioanalytical assays, immunological characterization of immune responses, and functional studies of antigen-specific human antibodies elicited from Tc bovine.

Dr. Wu has been leading numerous projects at SAB Biotherapeutics for the generation and development of Tc bovine-derived fully human antibodies against cancer and infectious diseases such as MERS-CoV, Ebola, Alphaviruses, Influenza, Hanta and mycoplasma.

Prior to this role, Dr. Wu was the Executive Director of Vaccinology and Antibody Characterization at Hematech Inc., a subsidiary of Kyowa Hakko Kirin Pharma, Inc. (KKP), where she led numerous research projects for the generation and characterization of Tc bovine-derived fully human antibodies against cancer and infectious diseases such as Anthrax, SARS, MRSA, and Botulinum toxin.  

Dr. Wu conducted her postdoctoral research in the Department of Cell Biology at Harvard Medical School. She received her Ph.D. in molecular and cellular biology from the University of Massachusetts at Amherst, and her M.S. in biochemistry and her B.S. in molecular biology from Jilin University in China.

P 605/679.6985
E hwu@sabbiotherapeutics.com